SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, and Pakistan's The Searle Company Limited (PSX: SEARL, ...

Teva Pharma receives European marketing approvals for Ponlimsi, biosimilar to Prolia and Degevma, biosimilar to Xgeva: Tel Aviv, Israel Thursday, November 27, 2025, 11:00 Hrs [IST ...

On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and ...

Pharma maker Dr. Reddy’s Laboratories Ltd. today announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar of Prolia (denosumab) and Xgeva (denosumab).

THOUSAND OAKS, Calif., May 20, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...

Amgen is celebrating the news that regulators in the USA have given a second green light to the biotech's key compound denosumab. Amgen is celebrating the news that regulators in the USA have given a ...

"Today's approval of XGEVA illustrates what is possible when scientific innovation, commitment and investment come together to advance medicine," said Kevin Sharer, chairman and chief executive ...

PONLIMSI will be available as a 60mg/1mL solution for injection in a pre-filled syringe. PONLIMSI is a biosimilar medicinal product, similar to the reference medicine Prolia® (denosumab), which was ...